Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) afatinib improves
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …

Background Dacomitinib is a first-line treatment for patients with non-small cell lung cancer
(NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations; however …

The advent of targeted therapies has radically changed the treatment landscape of
advanced non-small-cell lung cancer (NSCLC) harboring oncogenic drivers. Epidermal …

Introduction. The purpose of this study was to explore the efficacy and safety of afatinib in
advanced non‐small‐cell lung cancer (NSCLC) patients with epidermal growth factor …

肺癌的全球死亡率在所有恶性肿瘤中居首位, 2016 年我国癌症发病情况报道, 肺癌发病人数82.8
万, 死亡人数65.7 万. 目前对肺部罕见肿瘤的认识和研究仍存在局限性. 基于分子标志物的诊断 …

Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive
non-small-cell lung cancer: A case report - PMC Back to Top Skip to main content NIH NLM …

Background Some prospective studies have shown that second‐generation tyrosine kinase
inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) …